Kadmon Holdings Inc Quick Ratio (KDMN) starting from the third quarter 2021 to third quarter 2020, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Kadmon holdings inc   (NASDAQ: KDMN)

Kadmon Holdings Inc 's Quick Ratio

KDMN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2021, Quick Ratio fell to 5.65 above Kadmon Holdings Inc average.

Within Major Pharmaceutical Preparations industry 313 other companies have achieved higher Quick Ratio than Kadmon Holdings Inc in third quarter 2021. While Quick Ratio total ranking in the third quarter 2021 has deteriorated compared to the prior quarter from 644 to 1067.

Explain Quick Ratio?
How much Cash & cash equivalents KDMN´s has?
What are KDMN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KDMN Quick Ratio (Sep 30 2021)
Q3		 (Jun 30 2021)
Q2		 (Mar 31 2021)
Q1		 (Dec 31 2020)
Q4		 (Sep 30 2020)
Q3
Y / Y Current Liabilities Change 58.26 % 0.6 % 18.63 % 2.54 % -48.16 %
Y / Y Cash & cash equivalent Change 67.25 % 59.3 % 146.49 % 77.45 % 127.52 %
Quick Ratio MRQ 5.65 8.92 10.47 8.41 5.34
KDMN's Total Ranking # 1067 # 644 # 452 # 347 # 1120
Seq. Current Liabilities Change 47 % 7.3 % -4.13 % 4.66 % -6.56 %
Seq. Cash & cash equivalent Change -6.97 % -8.59 % 19.45 % 64.64 % -11.39 %



Quick Ratio third quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 314
Healthcare Sector # 524
Overall Market # 1067


Quick Ratio Statistics
High Average Low
10.47 4.05 0.46
(Mar 31 2021)   (Jun 30 2017)




Financial Statements
Kadmon Holdings Inc 's Current Liabilities $ 45 Millions Visit KDMN's Balance sheet
Kadmon Holdings Inc 's Cash & cash equivalent $ 252 Millions Visit KDMN's Balance sheet
Source of KDMN's Sales Visit KDMN's Sales by Geography


Cumulative Kadmon Holdings Inc 's Quick Ratio

KDMN's Quick Ratio for the trailling 12 Months

KDMN Quick Ratio

 (Sep 30 2021)
12 Months		 (Jun 30 2021)
12 Months		 (Mar 31 2021)
12 Months		 (Dec 31 2020)
12 Months		 (Sep 30 2020)
12 Months
Y / Y Current Liabilities TTM Growth 19.62 % -15.19 % -15.02 % -19.95 % -17.68 %
Y / Y Cash & cash equivalent TTM Growth 83.78 % 94.64 % 109.7 % 75.85 % 67.4 %
Quick Ratio TTM 8.04 8.3 7.45 6.17 5.23
Total Ranking TTM # 4568 # 4320 # 473 # 261 # 289
Seq. Current Liabilities TTM Growth 14.12 % 0.16 % 3.98 % 0.66 % -19.09 %
Seq. Cash & cash equivalent TTM Growth 10.49 % 11.66 % 25.56 % 18.64 % 17.02 %

Quick ratio ranking by company, industry and sector >> Back to KDMN Financial Strength Comparisons >> Go to Compare KDMN Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q3 2021 to $44.57 millions, cumulative Quick Ratio decreased to 8.04 above the KDMN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 498 other companies have achieved higher Quick Ratio than Kadmon Holdings Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2021 from 4320 to 4568.

Explain Quick Ratio?
How much Cash & cash equivalents KDMN´s has?
What are KDMN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 499
Healthcare Sector # 976
Within the Market # 4568


trailing twelve months Quick Ratio Statistics
High Average Low
7.23 3.55 0.84
(Jun 30 2021)   (Sep 30 2017)




Companies with similar Quick Ratio in the quarter ending Sep 30 2021, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2021 MRQ Cash & cash equivalentSep 30 2021 MRQ Current Liabilities
Kezar Life Sciences Inc   15.34 $ 120.759  Millions$ 7.872  Millions
Oncolytics Biotech Inc   15.34 $ 31.607  Millions$ 2.060  Millions
Tonix Pharmaceuticals Holding Corp   15.22 $ 183.001  Millions$ 12.026  Millions
Matinas Biopharma Holdings Inc   15.14 $ 53.830  Millions$ 3.556  Millions
Protagenic Therapeutics Inc new  14.98 $ 10.855  Millions$ 0.724  Millions
Oragenics Inc   14.93 $ 29.949  Millions$ 2.005  Millions
Connect Biopharma Holdings Limited  14.89 $ 267.716  Millions$ 17.985  Millions
Shattuck Labs Inc   14.63 $ 290.215  Millions$ 19.835  Millions
Royalty Pharma Plc  14.57 $ 2,113.569  Millions$ 145.055  Millions
Hepion Pharmaceuticals Inc   14.53 $ 98.731  Millions$ 6.797  Millions
Rezolute Inc   14.35 $ 37.292  Millions$ 2.598  Millions
Rhythm Pharmaceuticals Inc   14.35 $ 328.354  Millions$ 22.879  Millions
Oramed Pharmaceuticals Inc  14.34 $ 111.116  Millions$ 7.748  Millions
Enliven Therapeutics Inc   14.31 $ 102.839  Millions$ 7.188  Millions
Synlogic Inc   14.17 $ 150.054  Millions$ 10.591  Millions
Korro Bio Inc   14.12 $ 148.074  Millions$ 10.485  Millions
Inozyme Pharma Inc   14.01 $ 125.283  Millions$ 8.943  Millions
Whitehawk Therapeutics Inc   13.95 $ 161.375  Millions$ 11.567  Millions
Carisma Therapeutics Inc   13.91 $ 175.236  Millions$ 12.594  Millions
Cormedix Inc   13.81 $ 71.969  Millions$ 5.211  Millions
Rain Enhancement Technologies Holdco Inc   13.76 $ 150.081  Millions$ 10.904  Millions
Capricor Therapeutics inc   13.67 $ 40.839  Millions$ 2.988  Millions
Otonomy Inc   13.60 $ 87.096  Millions$ 6.402  Millions
Gain Therapeutics inc  13.31 $ 40.979  Millions$ 3.079  Millions
Stealth Biotherapeutics Corp  13.30 $ 47.135  Millions$ 3.545  Millions
Cellectar Biosciences Inc   13.30 $ 40.345  Millions$ 3.034  Millions
Praxis Precision Medicines Inc   13.06 $ 314.370  Millions$ 24.073  Millions
Arbutus Biopharma Corp  12.98 $ 112.224  Millions$ 8.643  Millions
Immunome Inc   12.83 $ 56.243  Millions$ 4.384  Millions
Vanda Pharmaceuticals Inc   12.76 $ 405.968  Millions$ 31.820  Millions

Date modified: 2026-09-08T15:10:24+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.